A prospective observational longitudinal study of new-onset seizures and newly diagnosed epilepsy in dogs by Fredsø, N. et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
A prospective observational longitudinal study of new-onset seizures and newly
diagnosed epilepsy in dogs
Fredsø, N.; Toft, N.; Sabers, A.; Berendt, M.
Published in:
BMC Veterinary Research
DOI:
10.1186/s12917-017-0966-y
Publication date:
2017
Document version
Publisher's PDF, also known as Version of record
Document license:
CC BY
Citation for published version (APA):
Fredsø, N., Toft, N., Sabers, A., & Berendt, M. (2017). A prospective observational longitudinal study of new-
onset seizures and newly diagnosed epilepsy in dogs. BMC Veterinary Research, 13, [54].
https://doi.org/10.1186/s12917-017-0966-y
Download date: 03. Feb. 2020
RESEARCH ARTICLE Open Access
A prospective observational longitudinal
study of new-onset seizures and newly
diagnosed epilepsy in dogs
N. Fredsø1*, N. Toft2, A. Sabers3 and M. Berendt1
Abstract
Background: Seizures are common in dogs and can be caused by non-epileptic conditions or epilepsy. The clinical
course of newly diagnosed epilepsy is sparsely documented.
The objective of this study was to prospectively investigate causes for seizures (epileptic and non-epileptic) in a
cohort of dogs with new-onset untreated seizures, and for those dogs with newly diagnosed epilepsy to
investigate epilepsy type, seizure type and the course of disease over time, including the risk of seizure recurrence.
Untreated client-owned dogs experiencing new-onset seizures were prospectively enrolled in a longitudinal
observational study including clinical investigations and long-term monitoring at the Copenhagen University
Hospital for Companion Animals. A baseline clinical assessment was followed by investigator/owner contact every
eight weeks from inclusion to death or end of study. Inclusion of dogs was conducted from November 2010 to
September 2012, and the study terminated in June 2014.
Results: One hundred and six dogs were included in the study. Seventy-nine dogs (74.5%) were diagnosed with
epilepsy: 61 dogs (77.2%) with idiopathic epilepsy, 13 dogs (16.5%) with structural epilepsy and five dogs (6.3%)
with suspected structural epilepsy. A non-epileptic cause for seizures was identified in 13 dogs and suspected
in 10 dogs. Four dogs in which no cause for seizures was identified experienced only one seizure during the
study. In dogs with idiopathic epilepsy 60% had their second epileptic seizure within three months of seizure onset.
Twenty-six dogs with idiopathic epilepsy (43%) completed the study without receiving antiepileptic treatment. The
natural course of idiopathic epilepsy (uninfluenced by drugs) was illustrated by highly individual and fluctuating seizure
patterns, including long periods of remission. Cluster seizures motivated early treatment. In a few dogs with a high
seizure frequency owners declined treatment against the investigators advice.
Conclusions: Epilepsy is the most likely diagnosis in dogs presenting with new-onset seizures. The course of idiopathic
epilepsy is highly individual and might not necessarily require long-term treatment. This must be considered when
advising owners about what to expect with regard to treatment and prognosis.
Keywords: Canine epilepsy, Idiopathic epilepsy, Epileptic seizure recurrence, Epilepsy remission, Non-epileptic seizures
Background
Seizures in dogs can arise from non-epileptic causes and
epilepsy. For owners of dogs with newly diagnosed epilepsy,
most common concerns relate to the possible source of sei-
zures, the risk of seizure recurrence, and prognosis.
Only few studies have investigated the distribution of
seizures caused by epilepsy versus other conditions [1–3],
whereas the risk of seizure recurrence in dogs with newly
diagnosed and untreated epilepsy is unknown. Such infor-
mation is of interest for the diagnostic and therapeutic
approach to seizure patients. Furthermore information
regarding seizure patterns in dogs with newly diagnosed
untreated epilepsy is of special interest, as it might influ-
ence recommendations regarding when to start treatment.
For humans with untreated epilepsy, a 2-year recur-
rence risk of 40% has been estimated after a first
unprovoked seizure [4–6].
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It is a matter of controversy whether the risk of poor
seizure control is increased if treatment is not initiated
soon after diagnosis [7]. Studies in untreated people with
epilepsy from resource poor countries have not found any
association between remission rates and the duration of
the epileptic condition or the total number of seizures
prior to treatment [8, 9]. Other studies have however
shown that the possibility of achieving long-term remis-
sion with treatment is higher for human patients treated
after the first seizure compared to those treated after two
or more seizures [10, 11]. Two human population studies,
randomizing patients to immediate treatment or
treatment only if a second seizure occurred, found that
treatment after a first seizure reduced the short-term (1–2
years) risk of seizure recurrence, but found no difference
between the two groups with respect to long-term
remission [5, 6]. Overall, the risk of a second seizure was
highest in the period shortly after the first seizure, and the
risk of seizure recurrence was higher in patients, which
had experienced two or more seizures at the time of
diagnosis [4, 5]. Furthermore a higher risk of seizure
recurrence has been documented in people with epilepsy
caused by a structural abnormality [4, 12, 13].
Only few studies have provided information to support
recommendations of when to initiate antiepileptic
treatment in dogs. A recent study investigating 334 dogs
with idiopathic epilepsy found that a high seizure density
before initiating treatment influenced the likelihood of
achieving remission with treatment negatively, while
neither seizure frequency nor the total number of sei-
zures prior to treatment influenced the likelihood of
remission [14]. An older study including 54 Labrador
Retrievers with idiopathic epilepsy reported a signifi-
cantly better treatment response in dogs with a low
seizure frequency and a low total number of seizures
prior to treatment, compared to dogs with a high
seizure frequency and a high total number of seizures
prior to treatment [15].
Prospective longitudinal studies in dogs with new-onset
seizures are desirable as they can serve to document the
likelihood of a diagnosis of epilepsy and illustrate the
course of epilepsy over time, including seizure recurrence
patterns [16]. Such information can also be useful when
trying to establish evidence-based recommendations re-
garding when to initiate therapy, and support clinicians
when trying to advice owners of dogs with epilepsy about
what to expect from the future.
The main aim of the present study was to investigate the
causes and characteristics of seizures in dogs presented
with new-onset seizures (epileptic or non-epileptic). For
dogs diagnosed with epilepsy, it was furthermore an aim to
report epilepsy type and associated seizure types and to
document the natural course of disease over time, includ-
ing seizure recurrence.
Methods
Study design, procedures and clinical assessment
The study was approved by the local institutional ethic
committee at University of Copenhagen (2010-6/NAFM)
and informed consent was obtained from the owners.
The study was conducted as a prospective observational
longitudinal study at the Copenhagen University Hos-
pital for Companion Animals. The recruitment period
lasted from November 2010 to September 2012, and the
study was terminated in June 2014. Included dogs were
monitored longitudinally including a baseline clinical as-
sessment followed by prescheduled investigator-owner
contacts every eight weeks (+/- two weeks). The dogs
were followed from inclusion to death or end of study.
The study population consisted of client-owned dogs
with a history of new-onset seizures. Only dogs which
were drug naïve with respect to antiepileptic drugs (with
the exception that prior treatment with diazepam for
acute seizures was allowed) could be included in the
study. Exclusion criterion was a first presentation of
seizures as status epilepticus (SE).
Dogs were recruited from Danish first-line veterinary
clinics and from the equally comparable first-line (com-
munity) Practice at the Copenhagen University Hospital
for Companion Animals in the following way: Veterinar-
ians were informed about the upcoming study through
oral presentations and a mailed pamphlet describing the
aim of the study, the inclusion and exclusion criteria and
the clinical study protocol. Furthermore, the contact in-
formation for the primary investigator (NF) was detailed.
The veterinarians were asked to support the study by
sending client-owned dogs presenting with a history of
new-onset seizures directly to the primary investigator
(meaning that seizure work-up was then performed for
all dogs by the primary investigator at the Copenhagen
University Hospital for Companion Animals specialized
Neurology Clinic). Dogs which fulfilled the above stated
study criteria were included consecutively into the study
by the primary investigator. All dogs included in the
study underwent a standardized clinical work-up (a
priori absolutely required diagnostic work-up) defined
by the prospectively designed study protocol (see below)
and all these clinical investigations were performed for
each single dog by the primary investigator.
In this study a seizure was defined as: “any sudden,
short lasting and transient event and does not imply that
the event is epilepsy” [17]. Epilepsy was defined as: “a
disease of the brain characterized by an enduring predis-
position to generate epileptic seizures. This definition is
usually practically applied as having at least two unpro-
voked epileptic seizures > 24 h apart” [17, 18].
Epileptic seizures were classified as primary generalized,
focal or focal seizure evolving to become generalized.
Post-ictal phase was defined as the time from end of
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clinical signs of seizure activity and until the dog regained
its normal behavior. Cluster seizures were defined as > 1
epileptic seizure within 24 h. Cluster seizures were consid-
ered a single seizure event.
Categorization of causes for seizures
Dogs could be categorized into one of four diagnostic
categories: 1) Epilepsy (idiopathic epilepsy, structural
epilepsy, suspected structural epilepsy), 2) Non-epileptic
seizures of identified origin, 3) Suspected non-epileptic
seizures of unidentified origin and 4) Single seizure
event (from inclusion to end of study) (Fig. 1).
A diagnosis of idiopathic epilepsy required two or
more epileptic seizures of intracranial/cerebral origin
occurring more than 24 h apart. Furthermore a normal
interictal physical and neurological examination and
blood profiles (complete blood count (CBC), biochemis-
try profile and thyroid profile (total thyroxin (TT4), free
thyroxin (fT4) and thyroid stimulating hormone (TSH)
within normal range (serving to secure that no other dis-
eases known to cause seizures were present). The seizure
semiology should be characterized by short-lasting con-
vulsions occurring alone (generalized epileptic seizure),
or by motor, autonomic or behavioral signs occurring
alone (focal epileptic seizure) or followed by convulsions
(focal epileptic seizure evolving to become generalized).
Furthermore in the individual dog, seizure semiology
should be identical from seizure to seizure. Furthermore
dogs should from inclusion to death or end of study stay
free of clinical signs of neurological disease indicating
brain pathology (structural epilepsy or suspected struc-
tural epilepsy) or any indication of extracranial disease
known to cause seizures and mimic epilepsy. Magnetic
resonance imaging (MRI) of the brain was strongly
recommended for all dogs, but owners could decline
due to ethical reasons. Computerized Tomography (CT)
and cerebrospinal fluid (CSF) analysis was recommended
by indication.
A diagnosis of structural epilepsy required two or more
epileptic seizures occurring more than 24 h apart where a
structural intracranial/cerebral cause for seizures was
identified by diagnostic imaging (MRI/Computer tomog-
raphy (CT), CSF analysis, or post mortem findings alone
or in combination.
In order to be categorized with suspected structural
epilepsy two or more epileptic seizures occurring more
Fig. 1 Flow diagram of the study
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than 24 h apart of suspected intracranial/cerebral origin
should have occurred. Intracranial/cerebral pathology
was thus strongly suspected but could not be confirmed,
typically because the owners declined further work-up
with MRI, CSF analysis and/or post mortem examination.
This category included e.g. dogs with a medical history of
previous head trauma or resolved cerebral disease, post-
disease occurring seizures and no indication of other dis-
eases known to mimic epilepsy, and dogs with interictal
clinical lateralized or focal neurological signs (progressive
or non-progressive) indicating localized cerebral brain
pathology.
Dogs were categorized with non-epileptic seizures of
identified origin if a non-epileptic cause of seizures was
identified by relevant diagnostic tests, or in case a known
breed specific episodic non-epileptic seizure-condition
such as e.g. idiopathic head tremor in the English bulldog
[19], was diagnosed.
Dogs were categorized with suspected non-epileptic
seizures of unidentified origin in cases where the clinical
appearance of seizures was atypical for epilepsy (e.g.
long-lasting >10 min seizures or solely exercise induced
seizure events) and where a cause for seizures could not
be identified based on the available diagnostic work-up
or because of incomplete work-up (typically if owners
declined the suggested diagnostic tests).
Baseline assessment
At inclusion a baseline clinical assessment (using the pro-
spectively designed study protocol) was performed by the
primary investigator (NF) at the Copenhagen University
Hospital for Companion Animals specialized Neurology
Clinic for all dogs participating in the study. All dogs were
investigated clinically using a problem oriented medical
record (POMR) approach and a differential diagnosis list
based on the mnemonic acronym DAMNIT-V. Clinical
investigations included the following: the dogs ID and sig-
nalment, full medical and seizure history, physical and
neurological examination, CBC, biochemistry and thyroid
profile. If a diagnosis other than epilepsy was suspected
relevant diagnostic tests such as e.g. echocardiography,
ultrasonography, radiographs and additional blood tests
were introduced in order to reach a final (differential)
diagnosis. For all dogs suspected of epilepsy MRI
was strongly recommended. Other specialized neuro-
diagnostic tests such as e.g. CT and CSF analysis
were performed by indication.
Seizure history was obtained as a face to face interview
using a structured questionnaire (Questionnaire A)
addressing age at seizure onset, date of first seizure and
date of subsequent seizures from first seizure to inclu-
sion, seizure frequency including time for seizures to
occur and possible occurrence of cluster seizures or sta-
tus epilepticus. Furthermore information was collected
regarding seizure semiology (focal and generalized phe-
nomenology), duration of seizure(s), possible seizure
triggering events, possible events preceding seizures, and
postictal phase. Finally, information was collected re-
garding, possible complications at birth, previous head
trauma or cerebral disease and possible relatives with
epilepsy.
All owners received a seizure calendar at the baseline
visit and were instructed to record the date(s), time of
day, duration and a detailed description of phenomen-
ology if any new seizures should occur. Furthermore the
owners were instructed to document seizure events on
video if possible. Video recordings of seizures were used
in the clinical evaluation.
For dogs with epilepsy where a need for treatment
arose after inclusion, antiepileptic treatment was
strongly recommended to the owner. The need for initi-
ating antiepileptic treatment was decided on a case by
case basis by the primary investigator (NF) in collabor-
ation with an experienced veterinary neurologist/and
human epileptologist (MB/AS).
Longitudinal monitoring of dogs
After the clinical baseline visit the owners were con-
tacted by telephone every eight weeks (+/- two weeks)
until death or end of study and interviewed. A struc-
tured questionnaire (Questionnaire B) comprising four
sections, was used for the telephone interviews:
1. Status (alive or dead): in case the dog had died since
last investigator-owner contact, the time of death
and cause of death were recorded.
2. Seizures since last follow-up: if new seizures had
occurred, the owners were asked about date of
seizure(s), seizure phenomenology, duration of
seizures and possible occurrence of cluster seizures
or/and status epilepticus.
3. Antiepileptic treatment: If receiving treatment, the
owners were asked to state product, strength and
dosage of the antiepileptic drug and to report
occurrence of potential adverse effects. Furthermore
owners were asked about possible owner initiated
changes in drug regimens.
4. Occurrence of other disease or any medication given
for other diseases than epilepsy since last
investigator-owner contact.
In order to secure a consistent and structured
evaluation of the dogs, all baseline investigations, in-
terviews, subsequent telephone contacts and clinical
investigations were performed for each single dog by
the primary investigator (NF). The owners could
furthermore contact the primary investigator at any
time throughout the study.
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Supplementary clinical control visits were conducted if
any of the telephone interviews indicated new seizures
(increase in seizure frequency) or any signs of progres-
sive neurological disease or other diseases, which could
promote seizures.
Dogs, in which a diagnosis of non-epileptic seizures of
identified origin was established during the study, were
subsequently referred to relevant hospital services for
further monitoring and treatment.
Statistical analysis
Descriptive analyses of qualitative data were performed
for the following groups: epilepsy (idiopathic and struc-
tural epilepsy), non-epileptic seizures of identified origin,
and suspected non-epileptic seizures of unidentified ori-
gin. Continuous data including age at seizure onset
(months), age at inclusion (months), weight at inclusion,
months of inclusion, age at death (months), numbers of
seizures prior to inclusion and survival time were pre-
sented for dogs with idiopathic or structural epilepsy
using median, range and quartiles (Q1-Q3). Median ages
at seizure onset were compared using Mann–Whitney U
test, a two-sided P value ≤ 0.05 was considered signifi-
cant. For dogs with idiopathic epilepsy, the time interval
(lengths of the interictal periods) from the first to the
second epileptic seizure, from the second to the third
epileptic seizure, and so on up to the fifth epileptic
seizure were calculated and presented as median and
quartiles (Q1-Q3). Dogs were included in this calcula-
tion up to the point where antiepileptic treatment was
initiated. For untreated and treated dogs with idiopathic
epilepsy, the number of dogs with a history of cluster
seizures was compared using a Fischer exact test, a two-
sided P value ≤ 0.05 was considered significant.
Results
One hundred and twenty-three dogs were screened for
study participation. Eight dogs failed inclusion due to
the study exclusion criteria, leaving 115 dogs. Out of the
115 dogs, four dogs were excluded because the owners
were unable to fully describe or document seizure events
and five dogs were lost for longitudinal monitoring
shortly after inclusion, leaving a final study population
of 106 dogs which completed the study from inclusion
to death or end of study. All dogs participating in the
study were family dogs that lived indoors and were
closely observed by their owners.
Seventy-nine dogs (74.5%) were diagnosed with epilepsy:
61 dogs (77.2%) with idiopathic epilepsy and 13 dogs
(16.5%) with structural epilepsy. In five dogs (6.3%) struc-
tural epilepsy was strongly suspected. Thirteen dogs
(12.3%) were categorized as having non-epileptic seizures
of identified origin and ten dogs (9.4%) were categorized
as having suspected non-epileptic seizures of unidentified
origin. Four dogs (3.8%) experienced only a single seizure
from seizure onset to the end of study, and no cause for
the seizure event was identified. The distribution of dogs
into the diagnostic categories appears from Fig. 1. Charac-
teristics of the dogs in specific diagnostic categories are
detailed in the following.
Dogs with idiopathic epilepsy
Of the 61 dogs, 83.6% were purebred (distributed among
29 different breeds) and 16.4% were crossbreeds. Median
age at seizure onset was 35 months (range: 5–114).
Additional descriptive information of the dogs is pre-
sented in Table 1. At the time of study termination, 45
dogs were still alive, whereas 16 dogs had been eutha-
nized. Ten dogs (62.5%) were euthanized due to epilepsy
related causes, while in six dogs (37.5%) euthanasia was
motivated by other non-neurological conditions. MRI
was performed in 30 dogs (49%) of which 20 dogs also
had a CSF analysis. All tests were normal. No clinical
indications of other intra- or extracranial disease were
identified for any of the 61 dogs from inclusion to death
or end of study.
Twelve dogs (19.7%) experienced focal seizures alone,
whereas 34 dogs (55.7%) experienced focal seizures
evolving to become generalized, and 11 dogs (18.0%)
had primary generalized seizures. In four dogs (6.6%) it
was not possible to classify seizure type because owners
were unable to describe if convulsions were preceded by
other events e.g. cases where the owner would wake up
at night finding the dog seizing. In 53 dogs (86.9%) the
owners reported a postictal phase lasting more than two
minutes.
The median number of epileptic seizures prior to
inclusion was three (Q1-Q3: 2–4, range 1–11) and the
median time of inclusion in the study was 28 months
(Q1-Q3: 23–32, range 3–42). Only four dogs were
included in the study for less than 12 months due to
euthanasia; three of these dogs were euthanized because
of severe epilepsy and poor seizure control and one dog
was euthanized because of severe elbow dysplasia. MRI
and CSF analysis were performed in three and two of
the four dogs, respectively, with normal results.
The median time interval between epileptic seizures
from the first to the second seizure, the second to the
third seizure and so on up to the fifth seizure was esti-
mated in up to 48 dogs with idiopathic epilepsy (80%)
and ranged from a median of 50.5–72 days (Table 2).
Only untreated dogs in which the exact date of first seiz-
ure was known were included in the calculations and as
soon a dog started treatment it was excluded from calcu-
lations. Thirteen dogs were excluded from calculation,
as the exact date of first seizure was uncertain. No short-
ening of the median time interval between epileptic
seizures (from the first to fifth seizure) and thus no signs
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of an accelerating course of epilepsy was observed. A
second epileptic seizure occurred within one month of
the first in 14 dogs (29.2%), within three months in
additional 15 dogs (29 dogs in total) (60.4%) and within
one year in additional 15 dogs (44 dogs in total) (92.2%).
In four dogs a second seizure occurred between one and
two years after the first seizure.
Twenty-six dogs remained untreated (43%) from study
start to the end of study. Seizure recurrence (from seiz-
ure onset to end of study) is illustrated for 24 out of 26
untreated dogs in Fig. 2 (two dogs were excluded from
calculation, as the owner forgot to register a few seizures
in the seizure calendar). As it appears from Fig. 2 the
seizure patterns were characterized by being very indi-
vidual and fluctuating. Some dogs such as dog 1 and 14
experienced a progressive course of the disease, while
other dogs e.g. dog 9 and 11 experienced prolonged pe-
riods of seizure freedom. When looking at the lengths of
all interictal periods in the 24 dogs, the longest interictal
period was a median of 408.5 days (Q1-Q3: 334.25–639,
range: 238–1151), while the shortest interictal period
was a median of 20 days (Q1-Q3: 3–71, range: 1–559).
Thirty-five dogs (57%) started antiepileptic treatment
at some point during the study. When comparing un-
treated and treated dogs, significantly (P = 0.014) more
dogs in the treatment group had a history of cluster sei-
zures compared to the dogs, which remained untreated
reflecting that the primary investigator advocated for
early treatment in dogs with cluster seizures. However
the owners’ opinions also influenced the decision of
treatment as it appears from Fig. 2.
Eleven out of the thirty-five treated dogs participated
in a concurrent clinical trial where dogs were random-
ized to mono-therapy with either phenobarbital (n = 6)
or levetiracetam (n = 5) [20]. Of these, nine out of
eleven dogs experienced five or more seizures before
intiating treatment. For the remaining dogs mono-
therapy was instituted with phenobarbital (n = 22) or
with imepitoin (n = 2), which was approved in Europe
during the study. Against the primary investigators
recommendations, some owners declined starting an-
tiepileptic treatment in their dog, explaining why
some dogs e.g. dog 1, 6, 14 and 15 (Fig. 2) did not
receive therapy despite a high seizure frequency and
in some cases cluster seizures.
Table 1 Descriptive information for dogs with idiopathic or
structural epilepsy
Idiopathic Structural
N % N %
Status at study end
Alive 45 74 4 31
Deceased 16 26 9 15
Gender
Female 27 44 10 77
Entire 21 78 9 90
Neutered 6 22 1 10
Male 34 56 3 23
Entire 24 71 2 67
Neutered 10 29 1 33
Seizure type
Focal 12 20 1 8
Focal evolving into
generalized
34 56 9 69
Primary generalized 11 18 2 15
Unknown 4 7 1 8
Diagnostic work-up
Magnetic resonance imaging 30 49 9 69
Computed tomography 0 0 4 31
Cerebrospinal fluid analysis 20 33 6 46
Post mortem histopathology 1 2 6 46
Seizure severity
Cluster seizures
(prior to inclusion)
18 30 12 92
Status epilepticus
(prior to inclusion)
2 3 0 0
Median age at seizure onset
(months)a
35 (range: 5–114) 59 (range 3–144)
Median age at inclusion
(months)
43 (range: 13–119) 48 (range: 3–146)
Median months of inclusion 28 (range: 1–42) 1 (range: 0–38)
Median weight at inclusion
(kg)b
23.9 (range: 2–71) 8.9 (range: 2.2–32)
Survival
Survival time (months) 23 (range: 3–65) 2 (range: 0–49)
aSeven dogs with idiopathic epilepsy and two dogs with structural epilepsy
excluded, as exact date of onset was unknown
bThree dogs with idiopathic epilepsy excluded from calculation, as weight at
onset was unknown
Table 2 Median time interval from the first to the fifth seizure
in untreated dogs with idiopathic epilepsy
Number
of dogs
Median time between
seizures (days)
Q1-Q3
From 1st to 2nda 48 72 27.75–156.25
From 2nd to 3rdb 46 50.5 20.5–120.5
From 3rd to 4thc 42 52 29.5–123,75
From 4th to 5thd 35 55 15.5–175
aThirteen dogs excluded from calculation, as there was uncertainty of the
exact date of first seizure
bOne dog excluded, as it did not have a third seizure and one dog excluded
as treatment was initiated
cThree dogs excluded, as they did not experience a fourth seizure and one
dog excluded as treatment was initiated
dFour dogs excluded, as they did not experience a fifth seizure and three dogs
excluded as treatment was initiated
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Dogs with structural epilepsy
Out of 13 dogs with structural epilepsy, 92.3% were
purebreds (distributed among 11 different breeds) and
7.7% were crossbreeds. Median age at seizure onset was
59 months (range: 3–144). Additional descriptive infor-
mation on the dogs appears from Table 1. These cases
were characterized by anamnestic information or neuro-
logical findings (alone or in combination) indicating
structural brain pathology. Ten dogs (76.9%) experi-
enced focal seizures, which for nine dogs evolved to be-
come generalized and two dogs (15.4%) experienced
primary generalized seizures. In one dog (7.7%) it was
not possible to classify seizure type. Owners reported a
postictal phase lasting more than two minutes in all 13
dogs (100%). In all cases the diagnosis was confirmed
with MRI, CSF analysis and/or post mortem examin-
ation. Six dogs (46.1%) were diagnosed with inflamma-
tory disease, two dogs (15.4%) with neoplasia, two dogs
(15.4%) with malformation (hydrocephalus), one with
spongiform leucoencephalopathy (7.7%) and two dogs
(15.4%) with cerebral hemorrhagic lesions due to
Angiostrongylus Vasorum induced coagulopathy. In the
latter two dogs, the onset of seizures occurred five months
and four years respectively after the primary incident, pre-
sumably due to the post hemorrhagic chronic lesion.
At the time of study termination, four dogs (30.8%)
were still alive while nine dogs (69.2%) had been eutha-
nized due to the primary brain disease and progression
of epileptic seizures. Median survival time after diagnosis
was 2 months, range: 0–49 months.
No statistically significant difference in the median age
at seizure onset was found between dogs with idiopathic
epilepsy and dogs with structural epilepsy (P = 0.33).
Dogs with suspected structural epilepsy
Five dogs, of which three were females (all intact) and
two were males (both intact), presented with a history
indicating structural brain pathology or an abnormal
neurological examination, which indicated structural
epilepsy. This could, however, not be confirmed because
the owners declined advanced neuro-diagnostics such as
MRI, CSF analysis and post mortem examination. There
was no indication of other diseases known to mimic epi-
lepsy. At the end of the study two dogs were still alive
while three dogs had been euthanized. The two dogs,
that were still alive at the end of the study, were in-
cluded in the study for 24 and 29 months, respectively.
No progression in the number of seizures was observed
during the course of the study in any of the two dogs.
Dogs with non-epileptic seizures of identified origin
Thirteen dogs, eight females (six intact, two neutered)
and five males (four intact, one neutered) were included
in this group. The causes of seizures were confirmed as
cardiovascular syncope (n = 5), brachycephalic syndrome
(n = 2), Bulldog idiopathic head tremor (n = 2), immune
Fig. 2 Seizure recurrence in 24 untreated dogs with idiopathic epilepsy. Open circles = seizure. Black circles = end of study. Gray circles = cluster
seizure. Gray squares = Death/euthanasia
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mediated hemolytic anemia (n = 1), portosystemic shunt
(n = 1), nsulinoma (n = 1) and Border collie collapse
(n = 1). For nine dogs (69.2%) a triggering factor
(coughing, play, excitement or high activity) preceded
seizure events. Owners reported a post seizure recov-
ery phase lasting more than two minutes in eight
dogs (61.5%), while five dogs (38.5%) had a postictal
phase lasting less than two minutes. The different
diagnoses were equally distributed between dogs ex-
periencing a short and a long recovery phase after
seizures.
The median age at seizure onset in this group was
43 months (Q1-Q3: 15.25–79.75, range: 6–136; three
dogs were excluded from calculation, as the exact date
of seizure onset was uncertain).
No significant difference was found in the median age
at seizure onset between dogs with non-epileptic sei-
zures of identified origin and the two epilepsy types,
idiopathic epilepsy (P = 0.98) and structural epilepsy
(P = 0.79), respectively.
Dogs with suspected non-epileptic seizures of unidentified
origin
Ten dogs, seven females (six intact and one neutered)
and three males (all intact), were included in this group
All dogs had a normal clinical and neurological examin-
ation and had CBC, biochemistry and thyroid profiles
within normal ranges. The median age at seizure onset
was 43 months (Q1-Q3: 3–46, range: 3–104). One dog
was excluded from calculation, as the exact date of
seizure onset was uncertain.
Two dogs were suspected of cardiovascular disease, as
seizures only occurred in relation to high activity/acute
stressful situations and the ictal phase lasted less than a
minute with no postictal phase. In both cases the owners
declined Holter monitoring, radiographs, fluoroscopy
and other suggested diagnostic tests. MRI and CSF ana-
lysis were not performed. One dog was suspected of a
sleeping disorder. The owner documented an average of
10 seizure events occurring during sleep every night.
The owner declined MRI and CSF analysis, and explor-
ing antiepileptic treatment as an alternative diagnostic
test. A paroxysmal movement disorder was suspected in
three dogs in which seizure events were characterized by
episodic longer lasting (up to hours) involuntary con-
tractions of skeletal muscles (front leg in 1 dog, hind
limb in 1 dog, and involving several groups of skeletal
muscles in 1 dog) with absence of other clinical signs or
neurological signs and a normal neurological examin-
ation. These dogs appeared mentally bright and alert
during seizures. One of the dogs had MRI and CSF
performed with normal results (the dog with generalized
involuntary muscle contractions). Besides that, all owners
declined further diagnostics e.g. muscle biopsy. In the last
four dogs the seizures were classified as being of unknown
origin due to an atypical nature of the seizures and lack of
further diagnostic work-up.
At study termination eight dogs were still alive, while
two dogs had been euthanized due to other reasons than
seizures.
Discussion
The longitudinal study design of this observational study
allowed us to provide prospectively collected longitu-
dinal descriptive information about dogs with newly di-
agnosed epilepsy and its suspected and confirmed
differential diagnoses, which has not been done before.
We found that epilepsy was by far the most frequent
diagnosis in dogs presenting with a history of new-onset
seizures (excluding SE), which is important information
for first-line practitioners. The considerable individual
variation in epileptic seizure frequency and epileptic
seizure density in the group of dogs with idiopathic epi-
lepsy, which remained untreated throughout the study
certainly illustrated the unpredictable nature of epilepsy
and exemplifies the difficulties associated with predicting
the course of the disease and also underlines the fact
that some dogs might actually not need treatment.
Dogs with structural epilepsy were characterized by
anamnestic information or neurological deficits or both
at presentation indicating cerebral dysfunction, and this
represent an important clinical diagnostic marker. Focal
seizures evolving to become generalized were the most
common types of epileptic seizures in dogs diagnosed
with idiopathic and structural epilepsy, which is in
accordance with was has been reported previously
[21–24]. The distribution of focal onset seizures and
generalized seizures was similar between dogs with
idiopathic epilepsy and dogs with structural epilepsy,
and thus we did not find any indication that the seiz-
ure type can be a helpful clinical marker of specific
epilepsy etiology. The majority of dogs with epilepsy (idio-
pathic and structural) experienced a postictal phase lasting
more than two minutes, which was also the case for
approximately 60% of the dogs with non-epileptic seizures
of identified origin. Based on these findings, a postictal
phase lasting more than two minutes does not seem to ad-
vocate more for epilepsy than for a non-epileptic seizure
condition. Dogs with non-epileptic seizures of identified
origin were predominantly characterized by a history
where seizure events were preceded by a specific immedi-
ate triggering factor such as e.g. physical activity or excite-
ment, which might represent a clinical diagnostic marker.
With respect to age at seizure onset, no significant
difference was found in the median age at seizure onset
when comparing dogs with idiopathic and structural
epilepsy and epilepsy and non-epileptic seizures of iden-
tified origin. Our results indicate that age at seizure
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onset might not be a good clinical marker when seek-
ing to differ between epilepsy types (idiopathic and
structural) or between seizures of epileptic or non-
epileptic origin and thus contradicts previous sugges-
tions that age at seizure onset could be an indicator
of etiology [1, 3, 25]. We however acknowledge that
the number of dogs diagnosed with structural epilepsy
and non-epileptic seizures of identified origin was rela-
tively low, which might have affected the results. It would
be interesting to investigate the findings of the present
study in a future large-scale epidemiological study.
In humans, only around 40% experience recurrence of
seizures after a first unprovoked seizure [5, 6]. This was
not the case in the present study where only four dogs
(3.8%) experienced a single seizure and no seizure recur-
rence. We, however, believe that a number of dogs with
only one seizure are never registered, as owners might
await more seizures before seeking veterinary advice. It
is therefore highly possible that we have missed to
include such cases in our study and thus this result is
probably underestimated.
In more than half of the dogs diagnosed with idiopathic
epilepsy a second epileptic seizure occurred within three
months after the first epileptic seizure, and in 92% of the
dogs within one year. These findings are in accordance
with a retrospective study of the course of untreated
epilepsy in people with tonic-clonic seizures [26].
In humans as well as dogs it was for many years
claimed that “seizures beget seizures” [27]. Evidence-
based clinical information, which can support this
hypothesis is sparse, and at least in humans immediate
initiation of treatment does not seem to influence long-
term outcome [5, 6]. This is in accordance with the
present study where we could not demonstrate an accel-
erating course of idiopathic epilepsy when comparing
the median time interval between the first to the fifth
epileptic seizure in untreated dogs.
Seizure recurrence has previously been investigated in
one veterinary study, which found that the probability of
primary epilepsy (idiopathic epilepsy) was significantly
higher than a diagnosis of secondary epilepsy (structural
epilepsy) or reactive seizures, if the time between the
first and the second seizure exceeded four weeks [1].
The present study confirmed a median time interval be-
tween the first and the second epileptic seizure of more
than four weeks (72 days) in dogs with idiopathic
epilepsy.
The recently published consensus proposal from the
IVETF and the 2015 ACVIM Small Animal Consensus
Statement on seizure management in dogs recommends
initiation of long-term antiepileptic treatment when two
or more epileptic seizures have been observed within a
six month period [28, 29]. Our findings in untreated
dogs with idiopathic epilepsy, which were long-term
monitored, might however suggest that there is a poten-
tial risk of unnecessary treatment when antiepileptic
medication is initiated routinely after a second seizure
occurring within six months. As many idiopathic epilep-
sies in dogs (as opposed to humans) are familial (breed
related) and of a suspected genetic origin [30] the
decision of when to initiate antiepileptic treatment in
dogs with idiopathic epilepsy might need to be individu-
alized. This decision seems to be best rooted in current
knowledge about the characteristics of the course of
epilepsy in the breed in question (epilepsy phenotype),
including epileptic seizure phenomenology, epileptic
seizure frequency and density, the risk of cluster seizures
and status epilepticus, severity of post-ictal events and
response to treatment.
In nearly 60% of the dogs with idiopathic epilepsy a
need for antiepileptic treatment was identified at some
point during the study. In the present study the recom-
mendation on when to initiate antiepileptic treatment
was made on a case by case basis by the primary investi-
gator in collaboration with an experienced veterinary
neurologist/and human epileptologist. For all dogs with
cluster seizures therapy was strongly advised. For some
dogs it was necessary to institute treatment during the
study, whereas for the 26 dogs which remained un-
treated throughout the study, we had the opportunity to
follow seizure recurrence over a long period of time. We
could have chosen to set a fixed number of seizures to
have occurred as a starting point for initiating treatment,
but we deliberately chose not to do so in order to reflect
“real life” with epilepsy patients as much as possible. In
daily life with epilepsy patients any initiation of treat-
ment is based on a combination of the clinician’s recom-
mendations and the owner’s motivation - which we were
also able to document in the present study. Our
approach may have its limitations, but we still find that
our study provide important informative observational
data.
The fact that owners’ opinions indeed influence the
decision of when to start treatment was highlighted by
the present study (reflected in Fig. 2). This has also been
reported by other investigators [31–33]. Our study also
depicted that some owners will decline treatment against
the professional advice given by the veterinarian working
to improve the quality of life for the affected animal.
Eleven dogs with idiopathic epilepsy participated in a
concurrent clinical treatment trial [20], which potentially
could have been a confounding factor with respect to
the calculations concerned with investigating the risk of
an accelerating course of epilepsy (from the first to the
fifth epileptic seizure). The risk of confounding is
however considered minor, as the majority of these
dogs (n = 9) experienced 5 or more seizures before
initiating treatment.
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A history of cluster seizures was significantly present in
the treated dogs compared to those that remained un-
treated. This is however not surprising, as prompt initi-
ation of antiepileptic treatment as a rule is recommended
for dogs experiencing cluster seizures [28, 29, 34]. This
was also the case in the present study.
Twelve percent of the included dogs in our study were
diagnosed with non-epileptic seizures of identified ori-
gin. This is in accordance with two previous studies,
which found an underlying metabolic or toxic cause in
10% and 11% of dogs suffering from seizures [1, 2].
In two dogs, the cause of epileptic seizures was evalu-
ated to be a post hemorrhagic cerebral lesion evidenced
by MRI and caused by a previous infection with Angios-
trongylus vasorum. Signs of neurological disease including
epileptic seizures have previously been described in dogs
in the acute states of Angiostrongylus vasorum infection
[35, 36]. Late onset of epileptic seizures secondary to a
hemorrhagic incident is not well documented in dogs but
has been reported in humans [37, 38]. One human study
reported a median delay of seizures of nine months (Q1-
Q3: 3–23 months) from the hemorrhagic incident [38].
A common bias when investigating epileptic dogs in a
referral hospital setting is that such dogs cases are refer-
rals which are commonly dominated by severe epilepsy
characterized by a high seizure frequency and in some
cases pharmacoresistance, and thereby they might not
truly reflect a normally distributed population of epilep-
tic dogs. The dogs participating in the present study
were recruited after a median of three seizures and were
untreated at inclusion, which would also be a common
scenario in first-line practice. Thus we consider bias with
regard to an overrepresentation of severe epilepsy cases
to be minor.
We fully acknowledge that certain limitations are asso-
ciated with a longitudinal observational study design as
the present, e.g. the fact that investigators must respect
when owners decline some diagnostic tests in order to
comply with the overall ethical rules associated with
studies including companion dogs. This is also the case
in first-line clinics. MRI could therefore not be per-
formed in all dogs diagnosed with idiopathic epilepsy,
why it cannot be excluded that structural epilepsy cases
e.g. occult developmental cerebral anomalies, slower
growing benign tumors, and silent vascular insults were
included in the group of dogs with idiopathic epilepsy.
However, diagnostic imaging was performed and
appeared normal in 49% of the dogs diagnosed with
idiopathic epilepsy, and furthermore the majority of dogs
were followed for a minimum of one year where they
did not develop any signs of neurological disease. This
longitudinal monitoring served to support the validity of
the diagnoses. Therefore we consider the likelihood of a
progressive intracranial lesion to be limited.
The benefits of using a prospective observational lon-
gitudinal study design (implicating pre-scheduled regular
investigator-owner contacts) is obviously the advantage
of being able to monitor clinical progression/regression
of disease and report data which is prospectively col-
lected over a longer period of time. This is not a possi-
bility with retrospective studies. Our study thus had the
design to illustrate the distribution of non-epileptic and
epileptic causes for seizures in dogs with new-onset
seizures, and furthermore contributed with a peace of
the puzzle forming the so-called “natural history of
epilepsy” [7].
Conclusions
The present study demonstrated that epilepsy is the
most probable diagnosis in dogs presenting with new-
onset seizures.. The consequences of a diagnosis of
idiopathic epilepsy are very individual and some dogs
may not need antiepileptic treatment. This information
can be useful for clinicians when advising owners of
dogs with new-onset seizures about which diagnostic
approach to take and what to expect with regard to
prognosis. Our results might also be of interest for
future epilepsy treatment recommendations.
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